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     Pancreatic cancer is the fourth leading cause of cancer-related death in 
the United States with an estimated 37, 390 deaths expected to occur in 
2012. The prognosis is very poor due to the recurrence and metastasis of the 
cancer with a 6% five-year survival rate for all stages combined. This study 
examined the effectiveness of dimethylamino-parthenolide (DMAPT) as a 
radiosensitizer to the human pancreatic cancer PaCa2 cell line. It is hypothe-
sized that DMAPT, a bioavailable drug derived from parthenolide, will inhibit 
the activation of NF-κB and enhance radiation-induced cell killing of PaCa2 
cells. NF-κB is a transcription factor that promotes cell survival, tumor pro-
gression, and angiogenesis and reduces susceptibility to apoptosis. The re-
sults show that DMAPT was toxic to the PaCa2 cell line. As a result, DMAPT 
suppressed cell growth and increased the doubling time of PaCa2 cells. The 
combination of 4μM DMAPT and radiation decreased cell survival. The PaCa2 
cell line is radiosensitized by DMAPT but further investigation is required to 
determine the mechanism through which DMAPT works. 
